432 related articles for article (PubMed ID: 18318369)
21. Advisory committees" critical to the FDA's product review process.
Rados C
FDA Consum; 2004; 38(1):17-9. PubMed ID: 15032199
[No Abstract] [Full Text] [Related]
22. ECRI comments on FDA's reuse plan.
Healthc Hazard Manage Monit; 2000 Jun; 13(10):4-5. PubMed ID: 11125912
[No Abstract] [Full Text] [Related]
23. Federal medical device regulations: what are the implications for respiratory care?
Gardner RM
Respir Care; 1988 Apr; 33(4):258-63. PubMed ID: 10315749
[No Abstract] [Full Text] [Related]
24. Medical device safety: FDA's postmarket transformation initiative.
Schultz D
Food Drug Law J; 2007; 62(3):593-6. PubMed ID: 17915401
[No Abstract] [Full Text] [Related]
25. FDA delays, unaccountability, raise health care costs and imperil American consumers' lives.
Lammi GG
Healthspan; 1995 Mar; 12(3):8-12. PubMed ID: 10166126
[No Abstract] [Full Text] [Related]
26. The FDA's response to the GAO's report: new effort to tighten the pre-market review process for select Class III medical devices.
Kim JH; Smith J; Greis J; Werling K
Health Care Law Mon; 2009 May; 2009(5):2-8. PubMed ID: 19449776
[No Abstract] [Full Text] [Related]
27. Doctors demand to see evidence on safety of medical devices approved in Europe.
Bowers S
BMJ; 2018 Nov; 363():k5105. PubMed ID: 30504128
[No Abstract] [Full Text] [Related]
28. New technology in electrophysiology: FDA process and perspective.
Selzman KA; Fellman M; Farb A; de Del Castillo S; Zuckerman B
J Interv Card Electrophysiol; 2016 Oct; 47(1):11-18. PubMed ID: 27020440
[TBL] [Abstract][Full Text] [Related]
29. Is it past time for third-party reviews?
Pilot L
Biomed Instrum Technol; 2011; 45(6):496. PubMed ID: 22107480
[No Abstract] [Full Text] [Related]
30. New efforts to harmonise clinical evaluation.
Donawa M
Med Device Technol; 2006; 17(9):28, 30, 32. PubMed ID: 17240684
[TBL] [Abstract][Full Text] [Related]
31. In the hot seat. Study questions FDA's fast-track process.
McKinney M
Mod Healthc; 2011 Feb; 41(8):16. PubMed ID: 21608192
[No Abstract] [Full Text] [Related]
32. Pharmaceuticals and medical devices: medical devices. Year end issue brief.
Tiffany S
Issue Brief Health Policy Track Serv; 2008 Jan; ():1-19. PubMed ID: 18345548
[No Abstract] [Full Text] [Related]
33. The blind hog and the acorn: Medicare coverage for investigational devices.
Betz R
J Healthc Resour Manag; 1995 Mar; 13(3):31-2. PubMed ID: 10154864
[No Abstract] [Full Text] [Related]
34. When to conduct a clinical trial.
Boutrand JP
Med Device Technol; 2004 Oct; 15(8):28-31. PubMed ID: 16225271
[TBL] [Abstract][Full Text] [Related]
35. Successful recruitment for medical device clinical studies.
Donawa M
Med Device Technol; 2004 Oct; 15(8):25-7. PubMed ID: 16225270
[TBL] [Abstract][Full Text] [Related]
36. Vioxx, radiology, and the Food and Drug Administration.
Pentecost MJ
J Am Coll Radiol; 2005 May; 2(5):394-7. PubMed ID: 17411841
[No Abstract] [Full Text] [Related]
37. Governmental regulation of medical devices.
Goodwin G
Respir Care; 1988 Apr; 33(4):251-7. PubMed ID: 10315748
[No Abstract] [Full Text] [Related]
38. Memorandum of understanding between the Food and Drug Administration and the Defense Alliance for Advanced Medical Terminology--FDA. Notice.
Fed Regist; 1998 Jul; 63(129):36700-6. PubMed ID: 10181056
[TBL] [Abstract][Full Text] [Related]
39. Let the spin begin. Greater transparency urged for device trials.
Becker C
Mod Healthc; 2005 Mar; 35(11):33. PubMed ID: 15794228
[No Abstract] [Full Text] [Related]
40. Remarks by the Commissioner of Food and Drugs at the twentieth anniversary celebration of the 1976 Medical Device Amendments.
Kessler DA
Food Drug Law J; 1996; 51(4):501-3. PubMed ID: 11797727
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
